MA54614A - Anticorps agonistes de flt3 et utilisations associées - Google Patents

Anticorps agonistes de flt3 et utilisations associées

Info

Publication number
MA54614A
MA54614A MA054614A MA54614A MA54614A MA 54614 A MA54614 A MA 54614A MA 054614 A MA054614 A MA 054614A MA 54614 A MA54614 A MA 54614A MA 54614 A MA54614 A MA 54614A
Authority
MA
Morocco
Prior art keywords
agonist antibodies
flt3 agonist
flt3
antibodies
agonist
Prior art date
Application number
MA054614A
Other languages
English (en)
Inventor
Melissa Beilschmidt
Johan Fransson
Phil Gobeil
Arif Jetha
Dorothea Maetzel
Original Assignee
Boehringer Ingelheim Io Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Io Canada Inc filed Critical Boehringer Ingelheim Io Canada Inc
Publication of MA54614A publication Critical patent/MA54614A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
MA054614A 2018-12-18 2019-12-17 Anticorps agonistes de flt3 et utilisations associées MA54614A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862781213P 2018-12-18 2018-12-18

Publications (1)

Publication Number Publication Date
MA54614A true MA54614A (fr) 2022-03-30

Family

ID=71101095

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054614A MA54614A (fr) 2018-12-18 2019-12-17 Anticorps agonistes de flt3 et utilisations associées

Country Status (22)

Country Link
US (1) US20220025055A1 (fr)
EP (1) EP3902836A4 (fr)
JP (1) JP2022513961A (fr)
KR (1) KR20210111785A (fr)
CN (1) CN113544152B (fr)
AU (1) AU2019404098A1 (fr)
BR (1) BR112021010948A2 (fr)
CA (1) CA3120063A1 (fr)
CL (1) CL2021001312A1 (fr)
CO (1) CO2021007689A2 (fr)
CR (1) CR20210327A (fr)
DO (1) DOP2021000114A (fr)
EA (1) EA202191650A1 (fr)
EC (1) ECSP21044672A (fr)
IL (1) IL283922A (fr)
JO (1) JOP20210151A1 (fr)
MA (1) MA54614A (fr)
MX (1) MX2021007339A (fr)
PE (1) PE20211474A1 (fr)
SA (1) SA521422309B1 (fr)
SG (1) SG11202104352XA (fr)
WO (1) WO2020128638A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020301161B2 (en) 2019-06-25 2023-10-26 Gilead Sciences, Inc. FLT3L-Fc fusion proteins and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635388A (en) * 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
DE19727814C1 (de) * 1997-06-30 1998-10-01 Univ Eberhard Karls Anitkörper 4G8B4B12
AR071891A1 (es) * 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
WO2011024113A1 (fr) * 2009-08-28 2011-03-03 Rinat Neuroscience Corporation Procédés de traitement de la douleur viscérale par administration d'anticorps antagonistes dirigés contre le peptide associé au gène de la calcitonine
WO2011076922A1 (fr) * 2009-12-23 2011-06-30 Synimmune Gmbh Anticorps anti-flt3 et leurs méthodes d'emploi
AR103896A1 (es) * 2015-03-09 2017-06-14 Agensys Inc Conjugados de fármacos de anticuerpos (adc) anti-proteínas flt3
TWI790120B (zh) * 2017-06-02 2023-01-11 美商輝瑞大藥廠 對flt3具特異性之抗體及其用途
PE20191847A1 (es) * 2017-06-02 2019-12-31 Pfizer Receptores de antigenos quimericos que se dirigen a flt3

Also Published As

Publication number Publication date
SA521422309B1 (ar) 2024-05-28
CN113544152B (zh) 2024-10-15
JOP20210151A1 (ar) 2023-01-30
CO2021007689A2 (es) 2021-06-21
CN113544152A (zh) 2021-10-22
WO2020128638A8 (fr) 2020-09-03
KR20210111785A (ko) 2021-09-13
SG11202104352XA (en) 2021-05-28
EA202191650A1 (ru) 2021-10-22
CA3120063A1 (fr) 2020-06-25
MX2021007339A (es) 2021-07-15
BR112021010948A2 (pt) 2021-08-31
EP3902836A1 (fr) 2021-11-03
CR20210327A (es) 2021-09-27
PE20211474A1 (es) 2021-08-05
WO2020128638A1 (fr) 2020-06-25
US20220025055A1 (en) 2022-01-27
DOP2021000114A (es) 2021-09-30
CL2021001312A1 (es) 2022-01-07
IL283922A (en) 2021-07-29
AU2019404098A1 (en) 2021-05-27
EP3902836A4 (fr) 2022-08-31
JP2022513961A (ja) 2022-02-09
ECSP21044672A (es) 2021-09-30

Similar Documents

Publication Publication Date Title
MA50144A (fr) Anticorps anti-peptides bêta-amyloïdes n3pglu et utilisations associées
MA53434A (fr) Anticorps anti-tigit
MA46525A (fr) Anticorps anti-lag-3 et compositions
MA52884A (fr) Anticorps anti-il-11
MA44659A (fr) Anticorps anti-tim-3 et compositions
MA47268A (fr) Anticorps anti-gpc3
KR102162129B9 (ko) 항-갈렉틴-9 항체 및 이의 용도
MA47311A (fr) Anticorps anti-tgf-bêta et leur utilisation
MA52414A (fr) Anticorps agonistes de pd-1 et leurs utilisations
MA49043A (fr) Formulation stable d'anticorps
MA46057A (fr) Anticorps anti-ctla4
MA52284A (fr) Anticorps anti-hla-g et leur utilisation
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
MA50038A (fr) Anticorps anti-pd-l1 de et son utilisation
MA52285A (fr) Anticorps multispécifiques et leur utilisation
MA52190A (fr) Anticorps anti-trem-1 et utilisations associées
MA47468A (fr) Anticorps anti-ilt3 et conjugués anticorps-médicament
MA45543A (fr) Anticorps anti-peptides n3pglu amyloïdes bêta et utilisations associées
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
MA49398A (fr) Anticorps monoclonaux anti-igf-1r et utilisations de ceux-ci
MA52152A (fr) Anticorps
MA52366A (fr) Anticorps anti-tl1a optimisés
MA47494A (fr) Nouvelles utilisations d'anticorps anti-sirpg
MA44236A (fr) Anticorps anti-tgfbêta 2
MA49133A (fr) Anticorps agonistes anti-btla et leurs utilisations